buy on dips strategy to follow for investment

ZYDUSLIFE Zydus Lifesciences Limited is one of India's established pharmaceutical companies, with operations across formulations, generics, active pharmaceutical ingredients (APIs), biosimilars, vaccines and specialty healthcare products. The company has a presence in domestic and international pharmaceutical markets, including the United States. Its diversified product portfolio and research capabilities provide opportunities for long-term business growth. Zydus Lifesciences reported the following consolidated financial performance for FY26: Financial parameter FY26 Operating revenue ₹27,148 Cr EBITDA ₹8,985 Cr Profit before tax ₹6,621 Cr Adjusted profit after tax ₹5,026 Cr Revenue growth 16.81% EBITDA growth 22.61% PAT growth 8.91% The financial numbers indicate healthy revenue and EBITDA growth. However, profit growth has been comparatively slower, which investors should monitor. The following levels are indicative technical reference levels based on the available market data: Technical levels Price Immediate support ₹1,225 Important support ₹1,200 Stronger support ₹1,170–1,150 Immediate resistance ₹1,250–1,255 Next resistance ₹1,267 Higher resistance zone ₹1,290–1,300